Health
Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026
Eisai announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), taking place in Chicago, Illinois from May 29 to June 2.
About this update from Eisai Co., Ltd.
[{"type":"text","content":"Real-World Evidence to be Presented Comparing First-Line Lenvatinib Versus Dabrafenib Plus Trametinib in BRAF-Mutated Differentiated Thyroid Cancer","length":147,"tagName":"p","attribs":{}},{"type":"text","content":"Additional Analysis from the Pivotal Phase 3 CLEAR Trial Examines Efficacy Outcomes by Patterns of Progression in Advanced Renal Cell Carcinoma with Lenvatinib Plus Pembrolizumab","length":178,"tagName":"p","attribs":{}},{"type":"text","content":"NUTLEY, N.J., May 20, 2026 /PRNewswire/ -- Eisai announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO26), taking place in Chicago, Illinois from May 29 to June 2.","length":289,"tagName":"p"},{"type":"image","alt":"Eisai logo. (PRNewsFoto/Eisai Inc.) (PRNewsfoto/Eisai Inc.)","displaySize":"","headline":null,"caption":"Eisai logo. (PRNewsFoto/Eisai Inc.) (PRNewsfoto/Eisai Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":270,"url":"https://media.zenfs.com/en/prnewswire.com/aaa30bce07a32677eb2fe4e6df05feff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Dahk8D_Izs3TVCsWzdg.Mw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3Ng--/https://media.zenfs.com/en/prnewswire.com/aaa30bce07a32677eb2fe4e6df05feff","width":400,"height":270},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/m.sUhDIq678kzJQmAjnZbg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQzMg--/https://media.zenfs.com/en/prnewswire.com/aaa30bce07a32677eb2fe4e6df05feff","width":400,"height":270}},"href":"https://mma.prnewswire.com/media/700351/Eisai_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Notable data include findings from a real-world evidence analysis comparing first-line lenvatinib (LENVIMA®), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, versus dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with BRAF-mutated differentiated thyroid cancer (DTC). The poster presentation will share insights from real-world clinical practice to inform treatment considerations for patients with this molecularly defined subset of DTC (Abstract #6052). Currently, lenvatinib is recommended as a preferred Category 1 systemic therapy regimen for the treatment of progressive, radioacti...